Regulation of LIF receptor expression in vascular smooth muscle


Autoria(s): World, C.; Rolfe, B. E.; Campbell, J. H.
Contribuinte(s)

Fujio Numano

Michael Gimbrone

Data(s)

01/01/2001

Resumo

Previous studies in our laboratory have shown that the pleiotropic cytokine leukemia inhibitory factor (LIF) inhibits neointimal formation and the development and progression of atherosclerotic and restenotic lesions in a rabbit model of disease. The present study demonstrates an upregulation of both the LIF receptor (LIFR)-α subunit and the signal transducing subunit gp130 following endothelial denudation of the carotid artery by balloon catheter. Continuous infusion of LIF (30 μg/kg/day) resulted in the downregulation of LIFR-a in injured arteries in vivo. Similarly, smooth muscle cells in vitro treated with LIF exhibited a time-dependent reduction in LIFR-a protein expression and the subsequent reduction in transcription of the TIMP-1 gene. However, in the presence of an intact endothelium, LIFR-a was upregulated in response to LIF, and accordingly the downstream induction of iNOS expression was also increased. Thus, LIF exerts more potent antiatherogenic effects in the vasculature when the endothelium is intact.

Identificador

http://espace.library.uq.edu.au/view/UQ:59419

Idioma(s)

eng

Publicador

New York Academy of Sciences

Palavras-Chave #Gp130 #Alpha #Kinase #Pathway #Stimulation #Internalization #Leukemia-inhibitory Factor #Vascular Smooth Muscle #Cytokine #Lif Receptor Expression #Leukemia Inhibitory Factor (lif) #Multidisciplinary Sciences #C1 #321003 Cardiology (incl. Cardiovascular Diseases) #730106 Cardiovascular system and diseases
Tipo

Journal Article